Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was conducted using clinical data of Japanese patien...

書目詳細資料
發表在:	BMC Cancer
Main Authors:	Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
格式:	Article
語言:	英语
出版:	BMC 2022-01-01
主題:	unresectable pancreatic cancer nomogram prognosis overall survival chemotherapy
在線閱讀:	https://doi.org/10.1186/s12885-021-09139-y

相似書籍

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
由: Masaru Fukahori, et al.
出版: (2023-11-01)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
由: Tsuyoshi Shirakawa, et al.
出版: (2023-05-01)

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
由: Tsuyoshi Shirakawa, et al.
出版: (2024-03-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
由: Taro Shibuki, et al.
出版: (2024-07-01)

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
由: Tomonori Araki, et al.
出版: (2025-01-01)

Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
由: Tomonori Araki, et al.
出版: (2025-02-01)

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
由: Tomoko Kodama, et al.
出版: (2024-05-01)

Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer
由: Keisuke Miwa, et al.
出版: (2025-07-01)

Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study
由: Takamichi Igarashi, et al.
出版: (2023-01-01)

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
由: Syvart Dennen, et al.
出版: (2025-08-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
由: Wenwang Lang, et al.
出版: (2024-11-01)

Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma
由: Ellery Altshuler, et al.
出版: (2022-06-01)

The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series
由: Pichit Sittitrai, et al.
出版: (2018-10-01)

Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report
由: Isabelle P. A. Magalhaes, et al.
出版: (2024-04-01)

Is there a place for liver transplantation in cases with unresectable central cholangiocarcinoma?
由: Nicolae Bacalbașa, et al.
出版: (2018-11-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
由: Ilario Giovanni Rapposelli, et al.
出版: (2021-05-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
由: T. Shirakawa, et al.
出版: (2025-06-01)

CLINICAL PROFILE AND MANAGEMENT OF PATIENTS WITH CARCINOMA GALL BLADDER
由: vinamra mittal, et al.
出版: (2025-06-01)

EXPERIENCE OF USING COMBINATION OF RADIOSURGERY AND RESECTION OF THE LIVER IN PATIENTS WITH EXTENSIVE METASTATIC DESEASE
由: A. A. Zaykov, et al.
出版: (2016-02-01)

The use of Sirolimus for an unresectable and refractory venous malformation: A case series
由: Daniela Kristina Carolino, MD, et al.
出版: (2025-06-01)

Systemic therapies for unresectable locoregional melanoma: a significant area of need
由: Emilia Nan Tie, et al.
出版: (2019-11-01)

The role of surgery for anaplastic thyroid carcinoma in the era of targeted therapeutics: A scoping review
由: Eoin F. Cleere, et al.
出版: (2023-12-01)

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure
由: Hui Tang, et al.
出版: (2025-09-01)

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
由: Lenka N.C. Boyd, et al.
出版: (2024-09-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
由: Masashi Sawada, et al.
出版: (2020-05-01)

Esophageal stenting for unresectable cancer (review of literature)
由: N. S. Popova, et al.
出版: (2021-01-01)

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
由: DENO Research Group, et al.
出版: (2025-01-01)

Surgical stage in sequential therapy of unresectable oral cancer T3-4bN0-3M0: evaluation of treatment results
由: Sh. I. Musin, et al.
出版: (2022-02-01)

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal
由: Amit Joshi, et al.
出版: (2015-01-01)

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
由: Marloes Faut, et al.
出版: (2018-06-01)

Stereotactic Body Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Observational Study from a Regional Cancer Center in South Asia—A Case Series
由: Arunkumar M.N, et al.

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
由: Zili Hu, et al.
出版: (2024-11-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
由: Emil Lou, et al.
出版: (2013-04-01)

Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy
由: Bahareh Farasati Far, et al.
出版: (2023-03-01)

A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
由: Ranpu Wu, et al.
出版: (2021-07-01)

Unresectable Advanced Gastric Cancer with Skin Invasion followed by Total Gastrectomy after Second-Line Chemotherapy
由: Hidenori Maki, et al.
出版: (2019-08-01)

Unresectable bulky chest wall recurrent breast cancer controlled with CT-guided interstitial high-dose-rate brachytherapy and external beam radiotherapy with adjuvant hormonal therapy – case report
由: Hiroaki Kunogi, et al.
出版: (2021-08-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
由: Yue Han, et al.
出版: (2021-10-01)

Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
出版: (2019-08-01)

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
由: Myles A. Ingram, et al.
出版: (2022-09-01)